Shanghai Miracogen

aka Miracogen, Shanghai Miracogen Inc., 美雅珂生物

Shanghai Miracogen is a Chinese antibody-drug conjugate developer whose HER2 conjugate MRG002 has been tested across breast, stomach, bladder and biliary cancers and whose EGFR conjugate MRG003 targets head and neck and nasopharyngeal cancer.

Shanghai Miracogen builds antibody-drug conjugates with site-specific conjugation and auristatin payloads. MRG002 links a HER2 antibody to monomethyl auristatin E and has been studied in HER2-positive and HER2-low breast cancer, gastric cancer, urothelial carcinoma and biliary tract cancer. MRG003 targets EGFR in nasopharyngeal and head and neck squamous carcinomas, and MRG004A targets tissue factor in pancreatic cancer.

Headquarters

Shanghai, CN

Scorecard

All companies

#297of 1181 companies, score 12

phase 3 +3
modalities +2
registry trials +7

0 approved, 1 in phase 3, 0 earlier, 0 targets, 11 registry studies. Formula on the scorecards page.

Type

biotech

Website

www.miracogen.com/

Founded

2015

Products

1top

Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record

MRG002

MRG002 is an experimental investigational agent whose form is not stated in the registry from Shanghai Miracogen in phase 3 trials for gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer, with its target not yet stated publicly.

Connected